Pyronaridine

Pyronaridine is an antimalarial drug.^[1] It was first made in 1970 and has been in clinical use in China since the 1980s.^[2]

Pyronaridine

Clinical data
Other names	Pyronaridine tetraphosphate
Routes of administration	Oral, intramuscular injection, intravenous therapy
ATC code	none
Legal status
Legal status	CLP (EU): Acute Tox. 3(H301), Eye Dam. 1 (H318), Repr. 2 (H361), Aquatic Chronic 4 (H413)[clarification needed]
Identifiers
IUPAC name 4-[(7-Chloro-2-methoxy-pyrido[3,2-b]quinolin-10-yl)amino]-2,6-bis(pyrrolidin-1-ylmethyl)phenol
CAS Number	74847-35-1 N
PubChem CID	5485198
ChemSpider	10647812 Y
UNII	TD3P7Q3SG6
ChEMBL	ChEMBL35228 Y
CompTox Dashboard (EPA)	DTXSID60996354
Chemical and physical data
Formula	C29H32ClN5O2
Molar mass	518.06 g·mol−1
3D model (JSmol)	Interactive image
SMILES Clc1ccc6c(c1)nc2ccc(OC)nc2c6Nc5cc(CN3CCCC3)c(O)c(CN4CCCC4)c5
InChI InChI=1S/C29H32ClN5O2/c1-37-26-9-8-24-28(33-26)27(23-7-6-21(30)16-25(23)32-24)31-22-14-19(17-34-10-2-3-11-34)29(36)20(15-22)18-35-12-4-5-13-35/h6-9,14-16,36H,2-5,10-13,17-18H2,1H3,(H,31,32) Y Key:DJUFPMUQJKWIJB-UHFFFAOYSA-N Y
NY (what is this?)  (verify)

In a small (n=88) malaria study in Camaroon, pyronaridine had a 100% cure rate, compared with 60% for chloroquine.^[3]

It is one of the components of the artemisinin combination therapy pyronaridine/artesunate (Pyramax).^[4]

It has also been studied as a potential anticancer drug,^[5] and treatment for Ebola. The combination of pyronaridine and artesunate has been evaluated to have a synergistic effect of stronger antiviral effect and less toxicity.^[6] The combination of pyronaridine and artesunate is being studied as a possible treatment for moderate to severe SARS-COV-2.^[7]